The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials

Authors

Gil Yosipovitch, Dr Phillip Frost Department of Dermatology and Itch Center, University of Miami, Miller School of Medicine, Miami, FL, USA.
Kim Papp, K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, Canada.
Seth Forman, Forman Dermatology and Skin Cancer Institute, Tampa, FL, USA.
George Han, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park.
Jill Waibel, Miami Dermatology and Laser Institute, Miami, FL, USA.
Maria J. Rueda, Eli Lilly and Company, Indianapolis, IN, USA.
Luna Sun, Eli Lilly and Company, Indianapolis, IN, USA.
Yun-Fei Chen, Eli Lilly and Company, Indianapolis, IN, USA.
Orin Goldblum, Eli Lilly and Company, Indianapolis, IN, USA.
Evangeline Pierce, Eli Lilly and Company, Indianapolis, IN, USA.
Jonathan I. Silverberg, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Document Type

Letter to the Editor

Publication Date

1-18-2022

Journal

The British journal of dermatology

DOI

10.1111/bjd.21015

APA Citation

Yosipovitch, Gil; Papp, Kim; Forman, Seth; Han, George; Waibel, Jill; Rueda, Maria J.; Sun, Luna; Chen, Yun-Fei; Goldblum, Orin; Pierce, Evangeline; and Silverberg, Jonathan I., "The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials" (2022). GW Authored Works. Paper 248.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/248

Department

Dermatology